Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.
Insider & Institutional Ownership
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 0.5% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Sunshine Biopharma and Foghorn Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.02 | -$5.97 million | ($12.90) | -0.09 |
| Foghorn Therapeutics | $28.22 million | 9.42 | -$74.28 million | ($1.16) | -3.91 |
Sunshine Biopharma has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Sunshine Biopharma has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500.
Profitability
This table compares Sunshine Biopharma and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -18.45% | -27.75% | -21.57% |
| Foghorn Therapeutics | -266.88% | N/A | -35.38% |
Analyst Recommendations
This is a summary of recent ratings for Sunshine Biopharma and Foghorn Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| Foghorn Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
Sunshine Biopharma presently has a consensus target price of $70.00, suggesting a potential upside of 5,882.91%. Foghorn Therapeutics has a consensus target price of $11.43, suggesting a potential upside of 152.29%. Given Sunshine Biopharma’s higher probable upside, equities analysts clearly believe Sunshine Biopharma is more favorable than Foghorn Therapeutics.
Summary
Foghorn Therapeutics beats Sunshine Biopharma on 9 of the 15 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
